Annual EBITDA
-$45.03 M
-$19.52 M-76.53%
31 December 2023
Summary:
Annovis Bio annual earnings before interest, taxes, depreciation & amortization is currently -$45.03 million, with the most recent change of -$19.52 million (-76.53%) on 31 December 2023. During the last 3 years, it has fallen by -$39.55 million (-721.39%). ANVS annual EBITDA is now -6499.50% below its all-time high of -$682.40 thousand, reached on 31 December 2017.ANVS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$4.39 M
+$3.38 M+43.48%
30 September 2024
Summary:
Annovis Bio quarterly earnings before interest, taxes, depreciation & amortization is currently -$4.39 million, with the most recent change of +$3.38 million (+43.48%) on 30 September 2024. Over the past year, it has increased by +$10.48 million (+70.48%). ANVS quarterly EBITDA is now -3128.55% below its all-time high of -$135.90 thousand, reached on 31 December 2019.ANVS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$30.40 M
+$10.48 M+25.63%
30 September 2024
Summary:
Annovis Bio TTM earnings before interest, taxes, depreciation & amortization is currently -$30.40 million, with the most recent change of +$10.48 million (+25.63%) on 30 September 2024. Over the past year, it has increased by +$11.99 million (+28.28%). ANVS TTM EBITDA is now -15901.21% below its all-time high of -$190.00 thousand, reached on 31 March 2018.ANVS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANVS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -76.5% | +70.5% | +28.3% |
| 3 y3 years | -721.4% | -53.8% | -195.6% |
| 5 y5 years | -6208.3% | -1714.6% | -3267.6% |
ANVS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -721.4% | at low | -53.8% | +70.5% | -195.6% | +32.5% |
| 5 y | 5 years | -6208.3% | at low | -3128.6% | +70.5% | -3392.1% | +32.5% |
| alltime | all time | -6499.5% | at low | -3128.6% | +70.5% | <-9999.0% | +32.5% |
Annovis Bio EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.39 M(-43.5%) | -$30.40 M(-25.6%) |
| June 2024 | - | -$7.76 M(-0.6%) | -$40.88 M(-4.7%) |
| Mar 2024 | - | -$7.81 M(-25.2%) | -$42.88 M(-4.8%) |
| Dec 2023 | -$45.03 M(+76.5%) | -$10.44 M(-29.7%) | -$45.03 M(+6.2%) |
| Sept 2023 | - | -$14.86 M(+52.3%) | -$42.39 M(+24.6%) |
| June 2023 | - | -$9.76 M(-2.1%) | -$34.01 M(+12.5%) |
| Mar 2023 | - | -$9.97 M(+27.8%) | -$30.23 M(+18.5%) |
| Dec 2022 | -$25.51 M(+75.9%) | -$7.80 M(+20.3%) | -$25.51 M(+8.0%) |
| Sept 2022 | - | -$6.48 M(+8.6%) | -$23.63 M(+18.2%) |
| June 2022 | - | -$5.97 M(+13.7%) | -$20.00 M(+20.8%) |
| Mar 2022 | - | -$5.25 M(-11.3%) | -$16.55 M(+14.2%) |
| Dec 2021 | -$14.50 M | -$5.92 M(+107.4%) | -$14.50 M(+41.0%) |
| Sept 2021 | - | -$2.85 M(+12.9%) | -$10.29 M(+21.7%) |
| June 2021 | - | -$2.53 M(-21.0%) | -$8.45 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$3.20 M(+87.7%) | -$8.26 M(+50.6%) |
| Dec 2020 | -$5.48 M(+529.8%) | -$1.70 M(+67.6%) | -$5.48 M(+40.1%) |
| Sept 2020 | - | -$1.02 M(-56.5%) | -$3.91 M(+24.7%) |
| June 2020 | - | -$2.34 M(+448.6%) | -$3.14 M(+182.9%) |
| Mar 2020 | - | -$425.70 K(+213.2%) | -$1.11 M(+27.4%) |
| Dec 2019 | -$870.50 K(+21.9%) | -$135.90 K(-43.8%) | -$870.60 K(-3.6%) |
| Sept 2019 | - | -$241.80 K(-21.0%) | -$902.80 K(+13.0%) |
| June 2019 | - | -$306.10 K(+63.9%) | -$798.70 K(+12.4%) |
| Mar 2019 | - | -$186.80 K(+11.1%) | -$710.80 K(-0.4%) |
| Dec 2018 | -$713.90 K(+4.6%) | -$168.10 K(+22.1%) | -$714.00 K(+30.8%) |
| Sept 2018 | - | -$137.70 K(-36.9%) | -$545.90 K(+33.7%) |
| June 2018 | - | -$218.20 K(+14.8%) | -$408.20 K(+114.8%) |
| Mar 2018 | - | -$190.00 K | -$190.00 K |
| Dec 2017 | -$682.40 K | - | - |
FAQ
- What is Annovis Bio annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Annovis Bio?
- What is Annovis Bio annual EBITDA year-on-year change?
- What is Annovis Bio quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Annovis Bio?
- What is Annovis Bio quarterly EBITDA year-on-year change?
- What is Annovis Bio TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Annovis Bio?
- What is Annovis Bio TTM EBITDA year-on-year change?
What is Annovis Bio annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ANVS is -$45.03 M
What is the all time high annual EBITDA for Annovis Bio?
Annovis Bio all-time high annual earnings before interest, taxes, depreciation & amortization is -$682.40 K
What is Annovis Bio annual EBITDA year-on-year change?
Over the past year, ANVS annual earnings before interest, taxes, depreciation & amortization has changed by -$19.52 M (-76.53%)
What is Annovis Bio quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ANVS is -$4.39 M
What is the all time high quarterly EBITDA for Annovis Bio?
Annovis Bio all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$135.90 K
What is Annovis Bio quarterly EBITDA year-on-year change?
Over the past year, ANVS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$10.48 M (+70.48%)
What is Annovis Bio TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ANVS is -$30.40 M
What is the all time high TTM EBITDA for Annovis Bio?
Annovis Bio all-time high TTM earnings before interest, taxes, depreciation & amortization is -$190.00 K
What is Annovis Bio TTM EBITDA year-on-year change?
Over the past year, ANVS TTM earnings before interest, taxes, depreciation & amortization has changed by +$11.99 M (+28.28%)